外周血淋巴细胞亚群联合程序性死亡配体-1表达在宫颈癌化疗联合免疫治疗疗效预测中的价值OA
Value of peripheral blood lymphocyte subsets and programmed death-ligand 1 expression in predicting efficacy of chemotherapy combined with immunotherapy for cervical cancer
目的 探讨外周血淋巴细胞亚群及肿瘤组织程序性死亡配体-1(PD-L1)表达水平对宫颈癌化疗联合免疫治疗疗效的预测价值.方法 选取124例接受化疗联合程序性死亡受体-1(PD-1)抑制剂治疗的宫颈癌患者(局部晚期74例、复发转移性50例)为研究对象.采用流式细胞术检测治疗前外周血CD3+、CD4+、CD8+T淋巴细胞及NK细胞比例;采用免疫组织化学法检测肿瘤组织PD-L1表达水平[联合阳性评分(CPS)].根据治疗后6个月疗效评估结果分为有效组(完全缓解+部分缓解)和无效组(疾病稳定+疾病进展),并比较2组免疫指标差异.采用Logistic回归分析筛选疗效的独立影响因素;采用受试者工作特征(ROC)曲线评估预测效能.结果 治疗前,有效组外周血CD3+T细胞、CD4+T细胞比例及CD4+/CD8+比值高于无效组,CD8+T细胞及NK细胞比例低于无效组,差异有统计学意义(P<0.001或P<0.01).PD-L1高表达组(CPS≥10,n=57)客观缓解率(ORR)为68.42%,高于低表达组(CPS<10,n=67)的37.31%,差异有统计学意义(x2=12.347,P<0.001).多因素 Logistic 回归分析显示,CD4+/CD8+比值(OR=3.421,95%CI:1.892~6.187,P<0.001)和 PD-L1 CPS(OR=2.876,95%CI:1.634~5.062,P<0.001)是宫颈癌化疗联合免疫治疗疗效的独立预测因素.纳入CD4+/CD8+比值与PD-L1 CPS(≥10)的联合预测模型的曲线下面积(AUC)为0.892(95%CI:0.831~0.953),优于单一指标.结论 外周血淋巴细胞亚群联合PD-L1表达水平可有效预测宫颈癌化疗联合免疫治疗疗效,两者联合的预测效能显著优于单一指标,具有重要的临床应用价值.
Objective To investigate the predictive value of peripheral blood lymphocyte subsets and tumor tissue programmed death-ligand 1(PD-L1)expression level for the efficacy of chemothera-py combined with immunotherapy in cervical cancer.Methods A total of 124 patients with cervical cancer(74 with locally advanced disease and 50 with recurrent or metastatic disease)who received chemotherapy combined with programmed death-1(PD-1)inhibitors were enrolled.The proportions of peripheral blood CD3+,CD4+,CD8+T lymphocytes and NK cells before treatment were detected by flow cytometry.The expression level of PD-L1 in tumor tissues was detected by immunohistochemistry using the combined positive score(CPS).According to the efficacy evaluation results at 6 months after treatment,the patients were divided into response group(complete response+partial response)and non-response group(stable disease+progressive disease),and the differences in immune indica-tors between the two groups were compared.Logistic regression analysis was used to identify inde-pendent influencing factors of efficacy,and the receiver operating characteristic(ROC)curve was used to evaluate the predictive performance.Results Before treatment,the proportions of peripher-al blood CD3+T cells and CD4+T cells,as well as the CD4+/CD8+in the response group were significantly higher than those in the non-response group,while the proportions of CD8+T cells and NK cells were significantly lower than those in the non-response group(P<0.001 or P<0.01).The objective response rate(ORR)of the high PD-L1 expression group(CPS ≥ 10,n=57)was 68.42%,which was significantly higher than 37.31%of the low expression group(CPS<10,n=67)(x2=12.347,P<0.001).Multivariate Logistic regression showed that the CD4+/CD8+(OR=3.421,95%CI:1.892-6.187,P<0.001)and PD-L1 CPS(OR=2.876,95%CI:1.634-5.062,P<0.001)were independent predictors of the efficacy of chemotherapy combined with im-munotherapy for cervical cancer.The area under the curve(AUC)of the combined prediction model incorporating the CD4+/CD8+ratio and PD-L1 CPS(≥ 10)was 0.892(95%CI:0.831-0.953),which was superior to that of any single indicator.Conclusion Peripheral blood lymphocyte subsets combined with PD-L1 expression level can effectively predict the efficacy of chemotherapy combined with immunotherapy for cervical cancer.The predictive performance of the combination is significantly superior to that of any single indicator,demonstrating important clinical application value.
苏佳奇;宋菲;李娜
山西医科大学附属运城市中心医院放射治疗科,山西运城,044000山西医科大学附属运城市中心医院放射治疗科,山西运城,044000山西医科大学附属运城市中心医院放射治疗科,山西运城,044000
医药卫生
宫颈癌淋巴细胞亚群程序性死亡配体-1免疫治疗化疗客观缓解率生物标志物肿瘤免疫微环境
cervical cancerlymphocyte subsetsprogrammed death-ligand 1immunothera-pychemotherapyobjective response ratebiomarkertumor immune microenvironment
《实用临床医药杂志》 2026 (16)
40-46,7
山西省重点研发计划项目(2025SKY-1059)
评论